Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.
Jose María Álvaro GraciaCarlos Sanchez-PiedraJavier ManeroMaría Ester Ruiz-LuceaLaura López-VivesCristina BohorquezJulia Martinez-BarrioGema BonillaPaloma VelaMaría Jesús García-VillanuevaMaría Teresa Navío-MarcoMarina PavíaMaría GalindoCelia ErausquinMiguel Angel González-GayInigo Rua-FigueroaJose M Pego-ReigosaIsabel CastrejonJesús T Sanchez-CostaEnrique González-DávilaFederico Díaz-Gonzáleznull nullPublished in: RMD open (2021)
The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.